Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced the company will review the interim results and business highlights on Monday, August 30,2021.
SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today the company will review the interim results and business highlights on Monday, August 30,2021. You can access the presentation through live webcast or dial-in.
- Mandarin Webcast and Teleconference
09:30 a.m. - 10:30 a.m. (Beijing Time)
- English Teleconference
09:00 a.m. - 10:00 a.m. (EDT)/ 09:00 p.m.- 10:00 p.m. (Beijing Time)
On the call, Kintor Pharma’s Founder, Chairman & CEO and CFO will provide an update on the company’s business and upcoming milestones. The conference call can be accessed by pre-registration. Once the registration has been approved, an email will be sent with dial-in number and password.
Registration Link: https://jinshuju.net/f/B5fDtH
Please kindly finish registration at least 24 hours before the call.
About Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia, and acne. For more information, visit www.kintor.com.cn.
View original content:https://www.prnewswire.com/news-releases/kintor-pharma-to-report-2021-interim-financial-results-and-host-conference-call-on-august-30-2021-301361359.html
SOURCE Kintor Pharmaceuticals
Company Codes: HongKong:9939
